Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus reuteri + bifidobacterium bifidum
- Development stage
- Preclinical
- Lead developer
- BioGaia
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus reuteri + Bifidobacterium bifidum is a combination of two probiotic bacterial strains. Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. This specific combination is being investigated for its therapeutic effects, particularly in neonatal conditions like bronchopulmonary dysplasia (BPD). The proposed mechanism involves modulation of the gut-lung axis, where altering the gut microbiota can influence systemic inflammation and immune responses. A study on a BPD cell model showed that this combination promoted cell proliferation, inhibited apoptosis, and reduced inflammation and oxidative stress. Both Lactobacillus and Bifidobacterium species are known to have immunomodulatory properties, including enhancing the gut barrier, producing antimicrobial substances, and influencing cytokine production.
02
Targets
AJC (Intestinal epithelial junctional complex)
Beyond the preview
Go deeper on lactobacillus reuteri + bifidobacterium bifidum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus reuteri + bifidobacterium bifidum.